products where more brands were available. The larger the brand premium, then the lower the market share of the premium brand. More multiple switchers were aged under 50 years (31%) than 70-79 years (20%). CONCLUSIONS: Multiple switches between SSRI brands occur in around one in four Australian Concessional patients and this has the potential to confuse some patients if not adequately monitored by prescribers and pharmacists. Switching rates increased where more brands are available on the PBS as well as in younger patients.
toid arthritis (RA) patients. METHODS: This cohort study used a population-based claim-data from the Kaopin Division of Taiwanese National Health Insurance during March 2006 to June 2009. Adult RA outpatients were identifi ed by diagnosis code, and followed from the fi rst prescription date (index date) of biological agents up to two months after discontinuation (prescription stop for more than 30 days) or the end of study. Prescription continuation rate between two drugs was evaluated using Kaplane-Meier survival curves and compared by the log-rank test. The frequencies of infectious events for new users of biological agents were also collected and the odds ratios of infectious events comparing etanercept against adalimumab were evaluated by logistic regression. RESULTS: Of all, 190 new users (mean age 53.43 ± 11.61 years; 83.68% female) were assessed. Most patients (70.53%) were prescribed biological agents in medical centers and 63.16% of them used etanercept. Total cumulative exposure time is 184.32 patient-years (145.86 patient-years in etanercept group, 38.46 patient-years in adalimumab group). Overall continuation rate for biological agents is 78.06% after 1 year, 55.04% after 2 years. The median continuation time is 836 days (95% CI 541, 972). Twenty-nine infectious events were detected; the most frequent events are pneumonia (seven events) and tuberculosis (six events). Patients who treated by etanercept had more infectious events than patients treated with adalimumab (OR: 5.99; 95% CI 1.55, 40.00). CONCLUSIONS: This study demonstrated that only half RA patients sustained their original biological therapy for more than 2 years. Furthermore, RA patients who treatd with etanercept acquired higher risk of infectious events. However, it is still necessary to further fi nd out reasons for discontinuation and to explore the causality between biological agents and infectious events.
PMS2 GASTROINTESTINAL AND CARDIOVASCULAR RISK OF NONSELECTIVE NSAIDS AND COX-2 INHIBITORS IN ELDERLY PATIENTS WITH KNEE OSTEOARTHRITIS
Turajane T Police General Hospital, Bnagkok, Thailand OBJECTIVES: To evaluate the risk for gastrointestinal (GI) events and cardiovascular(CV) events in patients >60 years with knee osteoarthritis using tNSAIDs or coxibs users. METHODS: A hospital-based retrospective cohort study was applied. Data on prescription drug (NSAIDs, celecoxib, etoricoxib) was obtained from June 2004 to June 2007 were included if they were aged >60 years. Patients with a history of gastrointestinal disease or heart disease were excluded. RESULTS: A total 12,591 prescriptions from 1030 patients, an average of four prescriptions/patient/year, were screened-3982 (31.6%) prescriptions were for NSAIDs, 4426 (35.2%) were for celecoxib, and 4183 (33.2%) were for etoricoxib. The most common traditional NSAID prescribed was meloxicam (24%). The mean age of cohort was 69.6 years, with the majority being female (74%). Comparing celecoxib with NSAID use in logistic regression analysis, patients who received celecoxib were signifi cantly less likely to suffer GI events than those who received NSAIDs; OR = 0.36 (95% CI 0.21-0.63, P = 0.00). Similarly, etoricoxib was less likely to cause GI events than NSAIDs; OR = 0.52 (95% CI 0.28-0.98, P = 0.04). Comparing to patients aged under 60 years, patients aged >70 years had a signifi cantly higher chance of developing GI events, OR = 1.79 (95% CI 1.13-2.4) for patients aged 70-80 years and 3.36 (95% CI 1.78-5.81) for those aged >80 years. Drug exposure time, signifi cantly increased the GI risks. For CV event, there were only three signifi cantly associated with CV events-female (OR = 0.29, 95% CI 0.16-0.59, P = 0.00), age > 80 years (OR = 2.98, 95% CI 1.57-4.23, P = 0.00), and drug exposure time (OR = 1.05, 95% CI 1.02-1.54, P = 0.00). CONCLUSIONS: Incidence of GI and CV events was lower for coxibs than for NSAIDs and celecoxib had a lower incidence than etoricoxib. Patients with advanced age and higher drug exposure time had a signifi cantly.
PMS3 THE RISK OF REFRACTURE ASSOCIATED WITH THE COMPLIANCE AND THE PERSISTENCE WITH BISPHOSPHONATE THERAPY IN TAIWAN
Su YJ 1 , Lin MJ 1 , Tsai IC 1 , Soong YK 2 1 Novartis Pharmaceuticals Corporation, Taipei, Taiwan, Taiwan; 2 Chang-Gung Memorial Hospital and The Taiwanese Osteoporosis Association, Taoyuan, Taiwan, Taiwan OBJECTIVES: To elucidate the relationship of the risk of refractures to compliance and persistence with bisphosphonate therapy in Taiwan. METHODS: We conducted a retrospective cohort study based on claims database of Taiwan's National Health Insurance (NHI) between 2003-2006. The study subjects included all new users of bisphosphonates. Compliance was estimated using a medication possession ratio (MPR), calculated as the total days of supply divided by the number of days between the fi rst and last dispensing plus the days of supply of the last dispensing. Persistence with bisphosphonate therapy was defi ned as continuous use, allowing for a refi ll gap of 30 days. RESULTS: The refracture rates of the osteoporosis patients increased with time. The refracture rate was 5.15%, 7.36%, and 8.49% at the fi rst, second, and third years, respectively. The refracture rate of patients with over 80% compliance was signifi cantly lower than those with a compliance below 80% (P < 0.05). The study found that nearly half of the patients were noncompliant with therapy (MPR < 80%) at as early as 3 months, and only around 30% of the patients were adherent at 1 year. The results also showed that the risk of refracture increased for patients with MPR < 80%, non-persistence, older patients and patients with comorbidities such as rheumatoid arthritis, diabetes mellitus or dementia. Patients with concomitant statin medication tended to have signifi cantly lower refracture risks than those without. CONCLUSIONS: From the study, the compliance and persistence of Taiwanese patients is poor. In addition, the study demonstrated that the risk of refracture is associated with the compliance and persistence with bisphosphonate therapy in Taiwan. The compliance and persistence issues for osteoporosis treatment warrant much more attention. To assess comorbidity, quality of life (QOL), work/productivity loss, and medical resource utilization in patients with rheumatoid arthritis (RA). METHODS: Patients' self-reported data were collected from 2009 National Health and Wellness Survey (NHWS). Survey samples represented major urban areas in China. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/productivity was measured by the validated Work Productivity and Activity Impairment (WPAI) instrument. Medical resource utilization was measured by health-care provider, emergency room (ER) visits and hospitalization in the past 6 months. Comparisons were made between respondents who suffer from RA (excluding psoriasis, psoriatic arthritis, or infl ammatory bowel disease) versus respondents without RA (non-RA group). RESULTS: Of the 13,307 survey respondents, 276 (2.1%) were diagnosed with RA, and the average age was 46.6 years. There were more females in RA group (59.5%) versus non-RA group (50.7%). RA group reported more diagnosed comorbidities (insomnia 43%, hypertension 24.7%, migraine 24.1%, allergies 23.4%, arrhythmia 22.8%, gingivitis 22.5%, dermatitis 18.9%, osteoporosis 16.9%, anemia 15.5%, bronchitis 13.9%, asthma 13.7%), lower mean scores of PCS (42.7 ` 48.5) and MCS (42.4 vs. 46.0), more patients visited health-care providers (83.3% vs. 56.3%), ER (48.5% vs. 18.9%) and hospitalized (25.0% vs. 7.0%) in the past 6 months compared to non-RA group. Also, RA group reported 37.8% work/ productivity loss (absenteeism and presenteeism) and 36.6% impairment in daily activity compared to 22.7% and 22.6% in non-RA group. All comparisons between RA and non-RA groups were statistically signifi cant at P < 0.05. CONCLUSIONS: From the China NHWS results, RA patients suffer from impairment in quality of life, work/productivity loss, more comorbidities and use of medical services. The fi ndings indicate there is still an unmet medical need in RA patients in China.
MUSCULAR-SKELETAL DISORDERS -Cost

PMS5
MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN-MULTI-CENTERED COST ANALYSIS
Tarumoto N 1 , Igarashi A 2 , Tarumoto E 3 , Harada T 3 , Fukuda T 4 1 Teikyo Heisei University, Tokyo, Japan; 2 Tokyo Univ. Faculty of Pharmacy, Tokyo, Japan; 3 Tarumoto Judo-Therapy Clinic, Tokyo, Japan; 4 Tokyo University, Tokyo, Japan OBJECTIVES: In the Judo-therapeutic fi eld, their costs are partly covered by National Health Insurance System via fee-for-service reimbursement, which does not necessarily refl ect actual costs. Therefore, the actual situation of medical practice in Judo-therapy Clinics (bone-setting clinics) is analyzed by comparison between the actual costs calculated by micro-costing methods and .reimbursement cost calculated by fee-forservice system. METHODS: The basis of this study is a bidirectional evaluation of single medical intervention in terms of actual cost and reimbursed cost for single treatment with following methods: 1) All receipts are collected from the participating bone-setting clinics for a fi xed period of time; 2) Along with collection of receipts, information on the medical interventions is recorded by region with regard to "how long" and "who" performed them; 3) The tentative cost of medical intervention is calculated based on the data in 2) above and the data of wage for the engaged persons. In other words, the tentative cost is calculated as the practitioner's wage per unit time multiplied by the time consumed; 4) The cost-based amount of individual medical intervention is calculated by adding indirect costs (wage for other staff than practitioner, cost for operation/maintenance of judo-therapy clinic) to the data in 3); and 5) Standard critical paths are made for several diseases, based on which medical expense for each therapy model is calculated in terms of both receipt-based amount and costbased amount, and a comparison of amount is made between them. RESULTS: Therapies in a total of 1646 regions were recorded, based on which a comparison was made using four diseases (lumbar sprain, neck sprain, femoral contusion, back contusion) as models. The receipt-based medical expense was JPY9030 (US$100) for all diseases, while the cost-based medical expense widely varied from JPY22,057 to JPY22,950 (US$245 to US$255). CONCLUSIONS: There was a signifi cant difference between the insurance benefi t amount and the actual cost of medical intervention in judo-therapy.
PMS6
HEALTH-CARE RESOURCE UTILIZATION AND OUTCOMES ANALYSIS OF OSTEOPOROTIC HIP FRACTURES AMONG THAI POST-MENOPAUSAL WOMEN: A PILOT INVESTIGATION
Reungjarearnrung K 1 , Chonglerttham S 2 , Permsuwan U 3 1 Bumrungrad Hospital, Bangkok, Bangkok, Thailand; 2 Bumrungrad Hospital, Wattana, Bangkok, Thailand; 3 Chiang Mai University, Muang, Chiang Mai, Thailand OBJECTIVES: Facing scarce data in Thailand on hospital costs of osteoporotic fractures, we examined repeated fractures and hospital costs incurred over 1 year from a primary osteoporotic hip fracture hospitalization occurred in postmenopausal women with or without comorbidities at Bumrungrad International Hospital in Bangkok. METHODS: Hospital admissions for primary hip fracture coded ICD-10 S 72.1 in post-menopausal women, aged 55 or older, were collected from January 2007 to January 2009. The hip fracture comorbidities considered were hypertension, type 2 diabetes, cardiovascular disease and their combinations. The repeated fractures within 6 or 12 months after fi rst admission were documented. All direct medical costs were retrieved from the hospital database looking at 1-year follow-up period. Statistical analysis employed unpaired t-test, Mann-Whitney U test and multivariate analysis for comparison of outcomes, costs and correlations to comorbidities. RESULTS: A total of 59 hospital admissions for diagnosed osteoporotic primary hip fracture in postmenopausal women were screened. Patients' mean age (SD) was 74.6 (7.7) years old, the mean hospital follow-up (SD) was 246.7 (77.5) days and the mean hospitalization duration (SD) was 17.0 (12.2) days. Patients at screening with and without comorbidities had similar characteristics including the types of fractures. The group with comorbidities was at higher relative risks of repeated fractures at 6 and 12 months follow-up compared to the group without comorbidities (1.13 vs. 0.91, P = 0.016; 1.10 vs. 0.94, P = 0.273, respectively) with consequently higher health-care utilization cost with 564,300 THB/patient/year versus 374,200 THB/patient/year, P = 0.043. The cost of all type drugs for both groups was only 8-10% of the total illness cost. CONCLU-SIONS: In osteoporotic post-menopausal women admitted at hospital for primary hip fracture, comorbidities increased risks of repeated fractures hospitalization as well as hospital costs. The cost of drugs was marginal among hospital costs of osteoporosis.
PMS7 A COST-EFFECTIVENESS ANALYSIS OF OSTEOPOROSIS TREATMENT FOR FRACTURE PREVENTION IN POSTMENOPAUSAL THAI WOMEN: A COMPARISON OF SEVEN TREATMENT OPTIONS
Pongchaiyakul C 1 , Songpattanasilp T 2 , Taechakraichana N 3 1 Khon Kaen University, Muang, Khon Kaen, Thailand; 2 Phramongkutklao Hospital and College of Medicine, Ratchathewi, Bangkok, Thailand; 3 Chulalongkorn University, Pathumwan, Bangkok, Thailand OBJECTIVES: To evaluate the cost-effectiveness of bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid), raloxifene, calcitonin and strontium ranelate, with a combination of calcium and Vitamin D as comparator, for the prevention of osteoporosis-related fractures in Thai post-menopausal women.
METHODS:
A Markov state transition model with 1-year cycle length was designed to simulate the cost-effectiveness of seven osteoporosis treatment interventions, compared with calcium and vitamin D, in Thai post-menopausal women aged 50-70 years. The model health states were categorized as osteopenia/no fracture, hip fracture, vertebral fracture, post-hip fracture, post-vertebral fracture and death. Treatment effects were obtained from published literature. The analysis was conducted using a societal perspective and included direct medical, direct nonmedical and indirect costs. Uncertainty was investigated by a probabilistic Monte Carlo simulation. Treatment outcomes were measured in terms of number of fractures avoided, number of life-years gained and quality-adjusted life-years (QALY) gained. Cost-effectiveness was defi ned as an ICER of less than 300,000 Baht (an incremental cost of ≤300,000 Baht for an outcome of no fracture for 1 year). RESULTS: 1) For patients with no prior fracture (primary prevention), zoledronic acid is cost-effective at ≥65 years, alendronate, risedronate and ibandronate at ≥70 years. 2) For patients with prior vertebral fracture (secondary prevention), zoledronic acid is cost-effective at ≥50 years, alendronate, risedronate and ibandronate at ≥55 years, raloxifene and strontium ranelate at ≥60 years; and 3) For patients with prior non-vertebral fractures, zoledronic acid is cost-effective at ≥60 years, alendronate at ≥65 years, and risedronate and ibandronate at ≥70 years. CON-CLUSIONS: Zoledronic acid, followed by other bisphosphonates, is the most costeffective treatment option for both primary and secondary fracture prevention in Thai postmenopausal women with osteoporosis. These fi ndings should be implemented in the government policy for selecting appropriate anti-osteoporotic drugs and reimbursement support strategy for Thai postmenopausal women with osteoporosis.
